Matugas, Keisha L.
HRN: 19-01-11 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/20/2022
CEFOTAXIME 500MG (VIAL)
05/20/2022
05/27/2022
IV
500 Mg
Q8
PCAP C
Waiting Final Action
Indication: Prophylaxis Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes